Document is current
Any future updates will be listed below
-
Authors
Wang, Wenshuai https://orcid.org/0000-0002-8713-9923
Götte, Benjamin https://orcid.org/0000-0003-4796-0423
Guo, Rong
Pyle, Anna Marie https://orcid.org/0000-0001-9045-8872
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI131518)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI131518)
Deutsche Forschungsgemeinschaft
- License Information
-
More Information
Article History
Received: 27 March 2023
Accepted: 25 October 2023
First Online: 11 November 2023
Competing interests
: A.M.P. has founded a company (RIGImmune) to develop SLRs as therapeutic agents. Yale University and A.M.P. have an issued patent on p3SLR14 (17/709,282), which was used in this study. The remaining authors declare no competing interests.
